Comment on “Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review” by Dajani et al.

Comment on “Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review” by Dajani et al.

Saved in:

Bibliographic Details
Main Authors:	Shubham Kumar, Rachana Mehta, Ranjana Sah, Edward Mawejje
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	Journal of Cachexia, Sarcopenia and Muscle
Online Access:	https://doi.org/10.1002/jcsm.13842
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series
by: Olav Dajani, et al.
Published: (2025-04-01)

Comment on “Expiratory time constants in mechanically ventilated patients rethinking the old concept: a narrative review”
by: Rachana Mehta, et al.
Published: (2025-04-01)

Comment on: “Prevalence and Influencing Factors of Malnutrition in Diabetic Patients: A Systematic Review and Meta‐Analysis”
by: Shubham Kumar, et al.
Published: (2025-03-01)

Comment: Admission neutrophil-to-lymphocyte ratio to predict mortality in burn patients: a meta-analysis
by: Nosaibah Razaqi, et al.
Published: (2025-03-01)

Comment on “Healthcare-Seeking Behaviour for Obstetric Complications in Ethiopia: A Multilevel Mixed-Effect Analysis”
by: Rachana Mehta, et al.
Published: (2025-08-01)

Comment on “Time Trends in Cardiovascular Event Incidence in New‐Onset Type 2 Diabetes: A Population‐Based Cohort Study From Germany”
by: Saraswati Sah, et al.
Published: (2025-07-01)

Comment on ‘Association of Computed Tomography‐Derived Body Composition and Complications After Colorectal Cancer Surgery: A Systematic Review and Meta‐Analysis’ by Van Helsdingen et al.
by: Rachana Mehta, et al.
Published: (2025-02-01)

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
by: Charlotte Pawlyn, et al.
Published: (2024-08-01)

Meta‐Analysis of Recurrence‐Free Survival or Disease‐Free Survival as a Potential Surrogate Endpoint for Overall Survival in Esophageal Cancer Trials
by: Uchechukwu Love Anyaduba, et al.
Published: (2025-05-01)

Editorial Comment From Dr. Chelsea and Dr. Ranjana to Zinner Syndrome Presenting With Chronic Pelvic Pain and Ejaculatory Dysfunction
by: Chelsea Rachael Tafawa, et al.
Published: (2025-07-01)

Measurement error and bias in real-world oncology endpoints when constructing external control arms
by: Benjamin Ackerman, et al.
Published: (2024-07-01)

Significance of biomarkers and surrogate endpoints in preclinical and clinical trials
by: Ilić Katarina, et al.
Published: (2007-01-01)

Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials
by: Shea E. Hogan, MD, MSCS, et al.
Published: (2025-06-01)

Comment on ‘Cachexia in Preclinical Rheumatoid Arthritis: Longitudinal Observational Study of Thigh Magnetic Resonance Imaging From Osteoarthritis Initiative Cohort’ by Moradi Et Al.
by: Liangping Zhang, et al.
Published: (2024-12-01)

Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues
by: Stephan vonHaehling, et al.
Published: (2025-06-01)

Cachexia index as a biomarker for cancer cachexia and quality of life in patients with gastric cancer
by: Yan Huang, et al.
Published: (2025-08-01)

Guillain-Barré Syndrome in Pune, India: Epidemiological and clinical insights into a potential waterborne outbreak
by: Sourav Sudan, et al.
Published: (2025-01-01)

Effect of Acalabrutinib in Combination with Bendamustine plus Rituximab on Survival Endpoints in Older Patients with Mantle Cell Lymphoma: Insights from the ECHO Trial
by: Adrian Schmidt
Published: (2024-12-01)

Expanding the use and interpretation of patient-centric cardiovascular clinical trial endpoints
by: Shelby D. Reed, et al.
Published: (2025-01-01)

A call for better reporting of trials using surrogate primary endpoints
by: Anthony Muchai Manyara, et al.
Published: (2022-01-01)

Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action
by: Nicole A. Tillie, et al.
Published: (2016-01-01)

Comment on ‘Impact of Cachexia and First‐Line Systemic Therapy for Previously Untreated Advanced Non‐Small Cell Lung Cancer: NEJ050A’ by Miura et al.
by: Wei‐Zhen Tang, et al.
Published: (2024-12-01)

Cancer Cachexia and MicroRNAs
by: Rodolfo Gonzalez Camargo, et al.
Published: (2015-01-01)

Takayasu’s Arteritis with Systemic Lupus Erythematosus: A Case Report
by: Himanshu Jindal, et al.
Published: (2025-06-01)

Landscape of clinical trials in cancer cachexia: assessment of trends from 1995–2024
by: Ana Regina Cabrera, et al.
Published: (2025-08-01)

Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
by: Martin Kortüm, et al.
Published: (2025-08-01)

Weight and Blood‐Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients
by: Steven D. Tran, et al.
Published: (2025-02-01)

Survival-inferred fragility of statistical significance in phase III oncology trials
by: Alexander D. Sherry, et al.
Published: (2025-07-01)

Marburg virus disease outbreak in Tanzania, 2023–2025
by: Ranjana Rohilla, et al.
Published: (2025-05-01)

Regulatory considerations for successful implementation of digital endpoints in clinical trials for drug development
by: Gül Erdemli, et al.
Published: (2025-03-01)

Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
by: Andrew R. DiNardo, et al.
Published: (2025-05-01)

Clinical trials for Wolfram syndrome neurodegeneration: Novel design, endpoints, and analysis models.
by: Guoqiao Wang, et al.
Published: (2025-01-01)

Reviewing History of Earthquake in 21st Century and Possible Infectious Diseases
by: Popat Mohite, et al.
Published: (2024-12-01)

Cachexia and Diffuse “Fish-Scale” Skin
by: Charith Sairam, et al.
Published: (2022-12-01)

Nonmuscle Tissues Contribution to Cancer Cachexia
by: Josep M. Argilés, et al.
Published: (2015-01-01)

Comment on ‘Detection of Cancer‐Associated Cachexia in Lung Cancer Patients Using Whole‐Body [18F]FDG‐PET/CT Imaging: A Multicentre Study’ by Ferrara et al.
by: Hao Chen, et al.
Published: (2024-12-01)

Multicomponent Interventions for Adults With Cancer Cachexia: A Systematic Review
by: Megan Bowers, et al.
Published: (2025-04-01)

Drug clinical trial landscape of chronic myeloid leukemia: achieving the endpoint or continuing the journey?
by: Shiyu Yang, et al.
Published: (2024-11-01)

Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials
by: Jeffrey C. Yu, et al.
Published: (2022-01-01)

Infantile Krabbe disease (0–12 months), progression, and recommended endpoints for clinical trials
by: Melissa R. Greco, et al.
Published: (2024-12-01)